BioSpace News Archive

Supernus Pharmaceuticals, Inc. announced it entered into a credit line agreement with UBS Bank USA providing the Company an uncommitted demand secured line of credit of up to $150 million, which can be drawn at any time.

Johnson & Johnson announced that Paula A. Johnson, MD, MPH, President of Wellesley College, has been appointed to its Board of Directors.

Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its second quarter fiscal year 2023.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced financial results for its third fiscal quarter and nine months ended December 31, 2022.

Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2023 ended December 31, 2022 (“Third Quarter”).

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced in February 2021.

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the fourth quarter and year ended December 31, 2022.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal first quarter 2023 ended December 31, 2022.

In collaboration with US-based Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and The Royal Adelaide Hospital, leading Australian CRO, Accelagen, is proud to announce that dosing has commenced in the Phase 1 first-in-human trial for KIO-301.

Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended December 31, 2022 (“Q2 FY 2023”).